EMA fast tracks review of a medicine for metastatic pancreatic cancer

Opinion/decision on a Paediatric investigation plan (PIP): Kapruvia, Difelikefalin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: EMA/PE/0000237641

Opinion/decision on a Paediatric investigation plan (PIP): Kerendia, finerenone, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Cardiac disorders, PIP number: EMA/PE/0000241538

PCWP/HCPWP joint meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 30 June 2026, 09:15 (CEST) to 1 July 2026, 12:00 (CEST)

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system, Bucharest, Romania, from 26 October 2026 to 28 October 2026

Qualification of novel methodologies for medicine development

Qualification of novel methodologies for medicinal product development: guidance to applicants

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 53, Status: Authorised

Agenda of the PRAC meeting 6-9 July 2026

Agenda of the HMPC meeting 6-8 July 2026